Castle Biosciences Inc — Liquidità Trimestrale (NASDAQ:CSTL) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Totale attivo 531.24 M501.71 M544.73 M562.79 M578.56 M Totale passività 75.4 M61.41 M89.35 M95.74 M107.68 M Patrimonio netto totale 455.83 M440.31 M455.38 M467.05 M470.87 M Totale passività e patrimonio netto 531.24 M501.71 M544.73 M562.79 M578.56 M Debito totale 10.12 M10.03 M10.04 M10.05 M10.16 M Indebitamento netto -456.43 M-450.58 M-454.01 M-479.48 M-472.12 M

Notizie

Il CEO di Castle Biosciences Maetzold vende azioni per 106.598$

Castle Biosciences: Buying The Remaining DecisionDx-Melanoma Upside (NASDAQ:CSTL)

Castle Biosciences, Inc. (CSTL) Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study Transcript

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU

FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents

United Therapeutics Stock Surges 32% in 6 Months: Here's Why

Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?

JNJ Seeks Label Expansion of Multiple Myeloma Drug Tecvayli in the EU

Stokes Frank vende titoli Castle Biosciences (CSTL) per 192.000$

Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k

LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata